Iliad Biotechnologies has licensed technology from Institut Pasteur de Lille, Inserm, National University of Singapore, and National University of Ireland Maynooth related to a live attenuated Bordetella pertussis vaccine, and the company says that it will work with the French National Institute of Health and Medical Research’s subsidiary Inserm Transfert and Institut Pasteur de Lille to develop an intranasal vaccine. Financial details were not disclosed.
The organizations cited a newly published article in PLOS One as evidence for the safety of the intranasal vaccine, called BPZE1, and its potential efficacy. The vaccine was developed by Professor Camille Locht of the Center for Infection and Immunity at Lille.
Iliad Biotechnologies CEO Keith Rubin said, “Global eradication of pertussis is the primary objective of Iliad Biotechnologies. Given the devastating impact of pertussis and the suboptimal performance of current pertussis vaccines, we believe the vaccine technology developed in Professor Locht’s laboratory holds enormous potential to prevent disease and save lives.” Inserm Transfert Executive VP, Open Innovation Augustin Godard added, “It is noteworthy that the BPZE platform may provide a wide variety of applications in the field of respiratory diseases.”
Read the Iliad/Institut Pasteur/Inserm press release.
